Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10497MR)

This product GTTS-WQ10497MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Osteoarthritis (OA), Migraine, Cluster headache (CH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ10497MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7807MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ2027MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AHLX-20
GTTS-WQ4637MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-986016
GTTS-WQ2862MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-570
GTTS-WQ39MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 2857916
GTTS-WQ942MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-321
GTTS-WQ3634MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ14729MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-19A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW